GlassScriptPhysician profile
Todd Driscoll Davis
NPI 1902865447
$1,780.61
in general payments reported to CMS, 2019-2025
24 companies · $20.89 in 2025
The $20.89 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,341 · 2020: $32.02 · 2021: $135 · 2022: $113 · 2023: $57.28 · 2024: $81.79 · 2025: $20.89.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $160.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $159.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $272.42 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $166.10 | 2019-2022 | |
| Glaxosmithkline, LLC. | $153.44 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $151.50 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $146.69 | 2019 | |
| Pfizer INC. | $134.03 | 2019 | |
| Nevro Corp. | $114.60 | 2023-2024 | Senza |
| Amgen INC. | $107.53 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $98.30 | 2019 | |
| Abbvie INC. | $79.78 | 2019-2023 | Dalvance |
| Janssen Pharmaceuticals, INC | $56.30 | 2019 | |
| Novartis Pharmaceuticals Corporation | $43.72 | 2019 | |
| Supernus Pharmaceuticals, INC. | $41.81 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $39.68 | 2019 | |
| Radius Health, INC. | $31.56 | 2019 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $26.54 | 2019 | |
| Amarin Pharma, INC. | $24.55 | 2019 | |
| Globus Medical, INC. | $20.89 | 2025 | Omnia |
| Alnylam Pharmaceuticals INC. | $19.72 | 2022 | |
| Allergan, INC. | $13.54 | 2019 | |
| Sanofi-Aventis U.S. LLC | $12.17 | 2019 | |
| Mylan Specialty L.P. | $11.75 | 2019 | |
| Eisai INC. | $11.31 | 2019 | |
| Fidia Pharma USA INC. | $2.68 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Todd Davis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.